The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

From basic research in academic labs to Phase 3 clinical trials, myriad efforts are underway to divorce opioids' pain-relieving potential from their undesirable downsides.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.